SCHEMBL18136167

SCHEMBL18136167

N/C(Cc1ccc2c(c1)nnn2O)=N\O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 9/20 0.49
TCF7L2 Q9NQB0 1/20 0.48
PKM P14618 1/20 0.44
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.41
NAMPT P43490 1/20 0.35
MAPT P10636 1/20 0.33
ALDH1A1 P00352 2/20 0.32
LMNA P02545 1/20 0.31
HCAR3 P49019 2/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
HTT P42858 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16406897 0.84 HCAR3 (0.46) POLBNAMPTMAPTALDH1A1HCAR3
SCHEMBL18127925 0.76 KMT2A (0.46) CTNNB1MAPTALDH1A1LMNAHCAR3
SCHEMBL18127926 0.76 KMT2A (0.46) CTNNB1MAPTALDH1A1LMNAHCAR3
SCHEMBL15185541 0.75 HCAR3 (0.36) NAMPTMAPTLMNAHCAR3NPC1
SCHEMBL22500208 0.74 CTNNB1 (0.56) CTNNB1TCF7L2PKMPOLBMAPK1
SCHEMBL3457708 0.71 CTNNB1 (0.52) CTNNB1TCF7L2PKMPOLBMAPK1
SCHEMBL3280470 0.71 CTNNB1 (0.59) CTNNB1TCF7L2PKMPOLBMAPK1
SCHEMBL16406901 0.70 HCAR3 (0.43) CTNNB1TCF7L2POLBMAPTALDH1A1
SCHEMBL16406916 0.67 CTNNB1 (0.46) CTNNB1
SCHEMBL16863946 0.67 PKM (0.58) CTNNB1TCF7L2PKMPOLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9738628-B2 Substituted 1H-indazol-1-OL analogs as inhibitors of beta catenin/Tcf protein-protein interactions UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2017-08-22 US disclosed
US-9738628-B2 Substituted 1H-indazol-1-OL analogs as inhibitors of beta catenin/Tcf protein-protein interactions UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2017-08-22 US disclosed
US-20160297801-A1 SUBSTITUTED 1H-INDAZOL-1-OL ANALOGS AS INHIBITORS OF BETA CATENIN/TCF PROTEIN-PROTEIN INTERACTIONS UNIVERSITY OF UTAH 2016-10-13 US disclosed
US-20160297801-A1 SUBSTITUTED 1H-INDAZOL-1-OL ANALOGS AS INHIBITORS OF BETA CATENIN/TCF PROTEIN-PROTEIN INTERACTIONS UNIVERSITY OF UTAH 2016-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297801-A1 SUBSTITUTED 1H-INDAZOL-1-OL ANALOGS AS INHIBITORS OF BETA CATENIN/TCF PROTEIN-PROTEIN INTERACTIONS CTNNB1, CTNNBL1, CTNNA1 CTNNB1 1/4885TCF7L2 10/4885PKM 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.